Functional activation of growth factors and receptors of the epidermal growth factor receptor
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …

Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading
cause of cancer-related death in North America. Most patients present with locally advanced …

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains
poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR is …

Purpose Patients with advanced pancreas cancer present with disease that is poorly
responsive to conventional therapies. Preclinical and early clinical evidence has supported …

Background Epidermal growth factor receptor inhibitors (EGFRI) produce various
dermatologic side effects in the majority of patients, and guidelines are crucial for the …

Purpose Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer.
Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) …

Pancreatic cancer is an aggressive disease that is predicted to become the second leading
cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around …

Multiple cellular pathways influence the growth and metastatic potential of tumors. This
creates heterogeneity, redundancy, and the potential for tumors to bypass signaling pathway …

Pancreatic cancer continues to pose an enormous challenge to clinicians and cancer
scientists. With a more affluent world the global incidence of pancreatic cancer is rising. For …